CoChat

Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy

Chrousos, George P., Harris, Alan G. · 1998 · Neuroimmunomodulation

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

In the first part of this two-part review it was noted that inhaled corticosteroids had become the mainstay of treatment for chronic asthma and yet the effects of long-term use of these compounds on the hypothalamic-adrenal-pituitary (HPA) axis were largely being determined by testing methods of limited reliability, especially by morning plasma cortisol measurements. It was established in our examination of the published literature and in our presentation of current knowledge of the structure and function of the HPA axis that safe, accurate and discriminating techniques to assess the functional status of the HPA axis were available. It was concluded that two state-of-the-art tests that have been insufficiently used were the ACTH stimulation test and measurement of the 24-hour integrated serial plasma cortisol concentrations. These two tests can detect adrenal suppression before the appearance of clinical effects. For part 2 of this review we conducted an exhaustive search of the English language clinical and pharmacological literature on the use of inhaled corticosteroids from 1988 until the present time to identify studies in which one or both of these testing methods have been used. We present our analysis of this limited number of studies to determine what accurately can be known of the HPA axis safety profile of three of the most commonly used and investigated inhaled corticosteroids – beclomethasone dipropionate, budesonide and fluticasone propionate. The first finding of significance was that only 50 reports were identified in which information on the HPA axis safety effects of orally inhaled steroids in asthma patients or in clinical pharmacological studies met our inclusion requirements. By analysis of the data presented in these reports we were able to reach the following conclusions: (1) inhaled corticosteroids administered chronically, and prudently, within recommended dose ranges do not endanger the functioning of the HPA axis, (2) the increasing tendency to use higher doses of inhaled corticosteroids on the assumption that there are clear dose-response benefits and no adverse HPA axis effects from long-term high-dose regimens is misguided and not supported by reliable published information, (3) the corollary – that higher corticosteroid potencies (as measured, for example, by skin-blanching activity) can have greater therapeutic effect in lung tissue without greater concomitant systemic activity – is a flawed concept, and (4) the limited clinical and pharmacological data support our part 1 conclusions that discriminating techniques to assess the functional HPA axis status should be an integral part of the drug development process and that further HPA axis function studies are required on existing inhaled corticosteroids – if they lack a rigorous testing history or long-term record of clinical safety.

Overview

Integrity signals

Registry

Crossref · 10.1159/000026349

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 4 references

Cited by

See all 48

Metadata

Authors
Chrousos, G. P., & Harris, A. G.
Affiliations
National Institutes of Health (US)
Venue
Neuroimmunomodulation
Publisher
S. Karger AG
Published
1998
Volume
5
Issue
6
Pages
288-308
ISSN
  • 1021-7401 (ISSN-L)
  • 1423-0216
OpenAlex
W2743422037
Cited by
48
References
4
Citations by year
2020: 2 · 2018: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 2
FWCI
1.34
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • NeuroImmunoModulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
hypothalamic-pituitary-adrenal axis, inhaled corticosteroids, adrenal suppression, persistent asthma, ACTH stimulation test, beclomethasone dipropionate, budesonide, fluticasone propionate, drug safety assessment, glucocorticoid potency
MeSH terms
Adrenal Cortex Hormones, Asthma, Humans, Hypothalamo-Hypophyseal System, Immunosuppression Therapy, Pituitary-Adrenal System, Neuroimmunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy. https://app.cochat.ai/papers/10.1159/000026349
The paper
Chrousos, G. P., & Harris, A. G. (1998). Hypothalamic-Pituitary-Adrenal Axis Suppression and Inhaled Corticosteroid Therapy. Neuroimmunomodulation. https://doi.org/10.1159/000026349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.